Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Legend Biotech Corp ADR shares valued at $11,959 were purchased by Yeung Jessie on Mar 25 ’25. At $35.28 per share, Yeung Jessie acquired 339 shares.
Also, Huang Ying purchased 4,064 shares, netting a total of over 143,371 in proceeds.
Before that, Sanders Corazon (Corsee) D. had added 307 shares to its account. In a trade valued at $11,153, the Director bought Legend Biotech Corp ADR shares for $36.33 each.
As published in their initiating research note from Redburn Atlantic on October 08, 2024, Legend Biotech Corp ADR [LEGN] has been a Buy and the price target has been revised to $86. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of May 24, 2024, H.C. Wainwright has reiterated its “Buy” rating for LEGN. Earlier on May 23, 2024, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for LEGN stock.
Analyzing LEGN Stock Performance
During the last five days, there has been a surge of approximately 2.33%. Over the course of the year, Legend Biotech Corp ADR shares have jumped approximately 5.22%. Shares of the company reached a 52-week high of $40.00 on 02/21/25 and a 52-week low of $29.27 on 04/09/25. A 50-day SMA is recorded $35.09, while a 200-day SMA reached $42.67.
Support And Resistance Levels for Legend Biotech Corp ADR (LEGN)
According to the 24-hour chart, there is a support level at 33.74, which, if violated, would cause prices to drop to 33.24. In the upper region, resistance lies at 34.78. The next price resistance is at 35.33. RSI (Relative Strength Index) is 52.18 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.79, which suggests the price will increase in the coming days. Percent R is at 17.83%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
